Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > BUSINESS
BUSINESS
- Takeda Taps Asuka Miyabashira as New Japan Pharma Chief
March 14, 2024
- Novo Gears Up Sustainability Efforts by Recycling Injectors in Japan
March 13, 2024
- Full Resumption of Quake-Hit Santen Plant Delayed into April
March 13, 2024
- Amgen’s Otezla Hits Primary Goal in PIII of Japanese PPP Patients
March 12, 2024
- Towa Develops Analytical Method for Nitrosamine in Antidepressant Duloxetine
March 12, 2024
- Sosei, Boehringer Ingelheim Join Hands in Schizophrenia Treatment
March 12, 2024
- Ono Forges Comprehensive Research Alliance with Harvard
March 12, 2024
- Genmab Files Epkinly for Follicular Lymphoma Grade 1-3A in Japan
March 12, 2024
- Xolair SC Pen Versions Approved in Japan: Novartis
March 11, 2024
- Eisai CEO Confident in Leqembi Uptake, Says 90% of US Hospital Targets to Adopt Med by March-End
March 8, 2024
- Japan Ethical Drug Sales Rise 5.6% in January: Crecon
March 8, 2024
- Keytruda Top-Seller Drug for 5th Straight Month in February: Encise
March 8, 2024
- Japan Generic Makers See Smaller Price Cuts in FY2024: Jiho Survey
March 7, 2024
- Majority of Drug Makers “Somewhat Satisfied” with FY2024 Revision: Poll
March 7, 2024
- Removal of PMP Company Indicators Most Popular Policy Change in FY2024 Reform: Poll
March 7, 2024
- Eisai Pledges Up to US$15 Million for Alzheimer’s Blood Test Player
March 7, 2024
- Takeda Triples Entyvio Production Capacity at Japan Site
March 7, 2024
- Sumitomo Pharma to Ax 400 US Jobs as it Rejigs North American Biz
March 7, 2024
- Ono Bags Cancer Drug License from South Korea’s NEX-I
March 7, 2024
- Tsumura Sees 24% Price Hike as Kampo Enjoys Boon in FY2024 Revision: Poll
March 6, 2024
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…